Last reviewed: May 17, 2026
Last updated: May 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Shed represents one of several GLP-1 telehealth platforms, but comparing any two programs requires understanding medication sourcing, quality standards, and personalization depth. Key differences include whether medications are compounded or branded, testing options, and provider consultation frameworks.
Choosing between GLP-1 programs involves more than pricing and convenience. PlexusDx emphasizes precision through licensed 503A compounding pharmacies and optional genetic insights that may help contextualize individual peptide pathway predispositions—supporting more informed conversations with qualified providers.
Understanding Medication Sourcing and Quality Standards
GLP-1 programs differ significantly in how medications are sourced and prepared. Some offer branded medications like semaglutide or tirzepatide, while others partner with compounding pharmacies. Compounding standards vary: 503A pharmacies operate under stricter state and federal oversight than 503B facilities, which primarily serve institutional settings.
PlexusDx partners exclusively with licensed 503A compounding pharmacies, meeting rigorous quality, sterility, and potency standards. This approach allows flexibility in dosing and formulation while maintaining pharmaceutical-grade safety protocols. Understanding your program's sourcing ensures confidence in medication preparation and consistency.
Program Structure, Provider Access, and Personalization Models
GLP-1 telehealth programs vary in initial assessment depth, ongoing provider interaction, and personalization options. Some offer minimal provider touchpoints, while others integrate regular check-ins, lab monitoring, and dose adjustments based on clinical response. Personalization depth directly impacts treatment outcomes and safety.
| Program Feature |
Typical Variation |
| Initial Provider Consultation |
Brief questionnaire vs. detailed medical history and clinical assessment |
| Ongoing Monitoring |
None vs. monthly check-ins with vitals, labs, and symptom review |
| Medication Adjustment Approach |
Fixed protocol vs. individualized titration based on response |
| Genetic or Biomarker Testing |
Not offered vs. optional genetic predisposition assessment |
| Pharmacy Partnership |
Multiple/unknown sources vs. exclusive licensed 503A partnerships |
Pricing, Access, and Cost Transparency
GLP-1 program costs typically range from $99 to $600+ monthly, depending on medication type, dose, and whether genetic testing or enhanced provider support is included. Branded medications often cost more than compounded alternatives. Some programs bundle initial assessments and ongoing care; others charge à la carte.
PlexusDx compounded semaglutide ranges from $149 monthly, while tirzepatide is $249 monthly. Optional Precision Peptide Genetic Testing costs $99 as an add-on or $298 standalone. Transparent pricing, combined with 503A compounding standards, allows patients to understand exactly what they're paying for and the quality assurance supporting it.
Safety Considerations and Who Should Seek Provider Guidance Before Starting
GLP-1 medications carry absolute and relative contraindications. Absolute contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Relative contraindications include severe gastrointestinal disease, diabetic retinopathy, and certain pregnancy contexts. Any telehealth program should screen for these before dispensing.
Qualified providers must evaluate your full medical history, current medications, and metabolic status before recommending any GLP-1 approach. PlexusDx connects you with providers who assess contraindications, set appropriate baseline labs, establish realistic goals, and monitor for side effects. This rigorous intake protects safety and improves adherence.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test examines predispositions in key peptide metabolism pathways—including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These variants may help provide context about how your body's genetic background relates to peptide pathway signaling, supporting a more personalized conversation with your provider about medication choice and expectations.
The genetic test reveals predispositions in peptide genetic pathways, not exact medication response or guaranteed outcomes. A variant linked to improved satiety signaling, for example, might inform your provider's discussion about starting dose or timing, but genetic data alone does not predict how you will respond clinically. Interpretation requires qualified provider guidance.
Understanding your genetic predispositions, combined with PlexusDx's 503A compounding partnerships and provider-led dosing flexibility, enables more granular clinical conversations. Your provider can contextualize genetic insights alongside your metabolic labs, symptom trajectory, and goals—moving beyond one-size-fits-all protocols toward precision-informed care.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between a 503A compounding pharmacy and other GLP-1 sources?
503A compounding pharmacies are state-licensed, regulated by state boards, and must meet strict quality and sterility standards. PlexusDx exclusively partners with 503A pharmacies for medication preparation, ensuring rigorous oversight and consistency.
How often should I expect provider check-ins on a GLP-1 program?
Best-practice GLP-1 programs include initial comprehensive assessment and regular follow-ups (often monthly) to monitor labs, adjust doses, manage side effects, and track progress. Frequency varies by program structure.
What does PlexusDx's Precision Peptide Genetic Test tell me?
The test examines genetic variants in peptide metabolism pathways (GIPR, GLP1R, FTO, MC4R). Results reveal predispositions but not guaranteed medication response. Findings should be interpreted with your provider to contextualize personalized GLP-1 strategy.
Are there serious safety concerns with GLP-1 medications?
GLP-1 medications have absolute contraindications (e.g., personal medullary thyroid cancer history) and relative contraindications (severe GI disease, certain pregnancy contexts). Qualified provider screening before starting is essential to assess individual safety.
Can I switch from a branded GLP-1 (like Ozempic) to a compounded version?
Yes, but only under provider guidance. Your provider must assess dosing equivalency, your clinical response history, and any reasons for switching. PlexusDx providers can evaluate whether compounded semaglutide or tirzepatide aligns with your goals and medical history.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Much Is Zepbound Without Insurance: Clinical Cost and Access Context
Maximus Alternative: Evaluating Compounded GLP-1 Options for Personalized Weight Management